💪 Generalised Body Aches

RCGP SCA Algorithm — UK Primary Care

RCGP SCA10-min consult
💪
Generalised Body Aches — New Presentation Systematic assessment of widespread musculoskeletal pain, myalgia and polyarthralgia
Progress 0 / 9

⚡ Snapshot. The whole pathway on one page: act now, triage, classify, treat today and safety-net. The Steps tab holds the detail.

Open full screen ↗
1
Safety

Red Flags — Exclude Serious & Systemic Pathology

Generalised body aches are extremely common — but these red flags demand urgent investigation.
Suspected GCA (aged 50+) New headache, scalp tenderness, jaw/tongue claudication, visual symptoms, constitutional symptoms or abnormal temporal artery examination → treat as an emergency. Take bloods urgently but do not delay corticosteroids awaiting results; arrange same-day review via the local fast-track GCA pathway (temporal artery ultrasound/biopsy per local arrangements). Visual, diplopia or neurological symptoms → same-day ophthalmology/acute assessment. Headache + myalgia alone is not sufficient to diagnose GCA.
Bone pain + hypercalcaemia symptoms Thirst, polyuria, confusion, fatigue → myeloma, bony metastases → urgent FBC, calcium, renal function, ESR/PV, serum protein electrophoresis + free light chains (NICE NG12). Severe hypercalcaemia or AKI → same-day admission
Progressive objective proximal weakness True weakness (not pain-limited movement) — difficulty rising from chair, combing hair; dysphagia, dysphonia, neck flexor or respiratory weakness, aspiration, rapidly rising CK or dark urine → inflammatory myopathy/rhabdomyolysis → urgent same-day medical assessment + specialist discussion (acute medicine, rheumatology, neurology, respiratory/swallowing teams by severity)
Fever + arthralgia Hot swollen joint → same-day hospital/rheumatology assessment and joint aspiration (septic arthritis). Blood cultures if sepsis, bacteraemia, infective endocarditis or serious bacterial infection suspected. Consider endocarditis, acute HIV, hepatitis B/C, parvovirus B19, disseminated gonococcal infection, Lyme disease (if exposure), thyroid disease, malignancy; reactive arthritis, viral arthralgia and adult-onset Still's disease have different work-ups
Rash + arthralgia SLE (butterfly rash), reactive arthritis (keratoderma blenorrhagica), psoriatic arthritis → urgent rheumatology referral
Dysphagia + myalgia Inflammatory myopathy (dermatomyositis can affect swallowing) → same-day medical assessment, swallowing assessment and aspiration-risk management + specialist discussion
Haematuria + arthralgia Vasculitis (ANCA-associated), SLE nephritis → urinalysis, urine ACR/PCR + renal function; renal, pulmonary or neurological involvement → immediate referral
Weight loss + night sweats Malignancy, TB, lymphoma — do not attribute to functional cause → bloods and the NICE NG12 route for the likely site
Delayed diagnosis of GCA risks sight loss — do not wait for ESR/CRP before starting steroids when suspicion is high. Distinguish true weakness from pain-limited movement: objective proximal weakness needs CK and urgent specialist assessment; dermatomyositis carries an associated malignancy risk and idiopathic inflammatory myopathy is a multisystem, specialist-led disease (BSR 2022). Myeloma can present with bone pain and fatigue — serum protein electrophoresis and serum free light chains identify the paraprotein. Vasculitis causing haematuria is a renal emergency — urgent ANCA testing and nephrology referral helps prevent irreversible kidney damage.
2
Diagnose

History — Pattern Recognition

Clarify the symptom
Is it pain, stiffness, joint swelling, tenderness or true weakness? Establish onset, duration, distribution and functional impact.
Distribution
Widespread (>3 months, above and below waist, both sides) → consider fibromyalgia. Bilateral shoulder and/or hip pain and stiffness → consider PMR. Joint swelling → inflammatory arthritis. Objective weakness → myopathy; pain without weakness → myalgia.
Onset & timing
Acute (<2 weeks) with fever → viral, infection. Subacute (weeks–months) → inflammatory, PMR. Chronic (>3 months) → fibromyalgia, chronic pain. Morning stiffness >45 min → inflammatory
Stiffness pattern
Morning stiffness >45 min improves with activity → inflammatory (RA, PMR, SpA). Stiffness all day, worse with activity → fibromyalgia, OA, mechanical.
Associated symptoms
Fatigue, sleep disturbance, cognitive fog (fibromyalgia triad). Rash, dry eyes/mouth (connective tissue disease). Raynaud's. Sicca symptoms.
Red-flag questions
Fever, weight loss, rash, headache, visual symptoms, jaw claudication, dysphagia, dark urine, neurological symptoms.
Post-viral / PEM
Post-exertional worsening, unrefreshing sleep, cognitive symptoms, orthostatic symptoms, functional decline → consider ME/CFS (NICE NG206).
Medication history
Statins (timing vs start/dose change; interacting medicines), steroids (myopathy, adrenal insufficiency on withdrawal), bisphosphonates, fluoroquinolones, colchicine → drug-induced myalgia
Psychosocial
Anxiety, depression, childhood adversity, PTSD, work stress, sleep — central sensitisation and pain amplification. PHQ-9 + GAD-7.
Morning stiffness duration is the most discriminating feature between inflammatory and non-inflammatory causes — >45 minutes strongly suggests inflammatory arthritis or PMR, while brief stiffness (<30 min) points toward mechanical or fibromyalgia. For statin-associated muscle symptoms, dechallenge and rechallenge are useful but not diagnostic in isolation. Central sensitisation (fibromyalgia, chronic widespread pain) is driven by maladaptive pain processing and is associated with psychological comorbidity — address co-existing depression and anxiety.
3
Diagnose

Differential Diagnosis by Pattern

Separate first
1) Pain without objective inflammation or weakness → consider chronic primary pain/fibromyalgia after assessment. 2) Objective synovitis → inflammatory arthritis, refer promptly. 3) Objective proximal weakness → myopathy; CK, urgent specialist assessment if progressive. 4) Proximal pain and stiffness 50+ with raised inflammatory markers → consider PMR after assessing mimics and GCA symptoms. 5) Systemic symptoms, bone pain, anaemia, hypercalcaemia or renal impairment → investigate for malignancy, myeloma or infection.
Fibromyalgia
A form of chronic primary pain. Clinical diagnosis: widespread pain, fatigue, unrefreshing sleep, cognitive fog, symptom severity and duration, with no more likely alternative diagnosis. Tender-point examination is not required; ACR criteria are not a mandatory GP diagnostic threshold. No blood test diagnostic.
PMR (age 50+)
Bilateral shoulder and/or hip pain and stiffness (periarticular — not primarily a muscle disease), morning stiffness >45 min. CRP/ESR usually raised — ESR may be normal in a minority; normal markers prompt reconsideration, not automatic exclusion. Consider mimics first: infection, malignancy, inflammatory arthritis, myositis, hypothyroidism, statin myopathy, paraneoplastic disease. Steroid response does not confirm PMR (BSR/BHPR). Onset usually >50 yrs.
Inflammatory arthritis
RA (small joints, symmetric, RF/anti-CCP), psoriatic arthritis (DIP joints, psoriasis), reactive arthritis (post-infective), SpA (sacroiliac, lower back, enthesitis)
Viral / post-viral
Influenza, EBV, CMV, parvovirus B19, COVID — acute myalgia + arthralgia. Usually self-limiting; persistent symptoms need reassessment. Post-COVID myalgia can persist months — distinguish post-exertional malaise and ME/CFS (NICE NG206; do not prescribe graded exercise therapy).
Endocrine myopathy
Hypothyroidism (proximal weakness, raised CK, slow reflexes), Cushing's (proximal weakness, cushingoid features), Addison's (generalised aches + fatigue)
Drug-induced
Statins (muscle symptoms — check CK, TFTs; marked weakness/dark urine → urgent), steroids (proximal myopathy), alcohol myopathy, fluoroquinolones (tendinopathy)
Vitamin D deficiency
Bone pain/osteomalacia, proximal myopathy. Test 25-OH vitamin D only with risk factors or a compatible syndrome — not routinely for aches. A low level may coexist with symptoms but is not automatically the cause. Treat if <25 nmol/L; 25–50 nmol/L — treatment depends on symptoms, risk factors and clinical context (NOS vitamin D guideline).
PMR is a common inflammatory condition in older adults. Many inflammatory and non-inflammatory conditions improve with steroids, so a response does not confirm PMR — but failure to respond should prompt reconsideration. Vitamin D deficiency is common in at-risk groups, but a low level is not automatically the cause of aches. Fibromyalgia and inflammatory arthritis can co-exist — consider both.
4
Diagnose

Targeted Examination

General
Fever, weight loss, lymphadenopathy, butterfly rash (SLE), heliotrope rash (dermatomyositis), Gottron's papules (dermatomyositis)
Joints
Swollen/tender joints (synovitis — warm, boggy → inflammatory), deformities, DIP involvement (psoriatic), sacroiliac tenderness (SpA)
Muscles
Proximal weakness: "Can you rise from a chair without using arms?", "Can you lift arms above your head?" — distinguish true weakness from pain-limited movement; objective weakness → myopathy. Widespread tenderness is common in fibromyalgia (tender-point counting not required).
Temporal arteries
Tenderness, thickening, absent pulsation — mandatory in all patients aged 50+ with new headache/scalp tenderness + myalgia
Skin
Psoriasis plaques (especially scalp, umbilicus, natal cleft), nail pitting (psoriatic arthritis), photosensitive rash (SLE), Raynaud's
Neurological
Slow relaxing reflexes (hypothyroidism), proximal weakness testing, sensory neuropathy (B12 deficiency, vasculitis)
The chair-rise test is a quick screen for proximal muscle weakness — inability to rise without arm support suggests proximal myopathy, provided pain is not limiting movement. The heliotrope rash (violaceous periorbital discolouration) and Gottron's papules (scaly erythematous papules over knuckles) are characteristic of dermatomyositis — this needs urgent specialist-led assessment including malignancy screening. Scalp, umbilical and nail examination for missed psoriasis is important in any arthritis presentation.
5
Diagnose

Investigations

Targeted basic tests (persistent, unexplained or clinically significant symptoms — not all patients)
FBC ESR/CRP U&E LFTs · TFTs where clinically indicated · Calcium if bone pain, malignancy, hyperparathyroidism or myeloma suspected · Glucose/HbA1c if clinically indicated
CK — only if
Objective proximal weakness, significant muscle tenderness, statin-associated symptoms with weakness, suspected inflammatory myopathy, rhabdomyolysis/dark urine, drug-related muscle toxicity. Not a routine test for all aches.
Vitamin D — only if
Risk factors or clinical suspicion: bone pain/osteomalacia, proximal weakness, malabsorption, limited sun exposure, darker skin, covered skin, frailty/falls, anticonvulsant or glucocorticoid treatment, chronic kidney or liver disease.
Inflammatory arthritis screen
Only with clinical synovitis or a convincing inflammatory arthritis pattern: RF · Anti-CCP — negative RF/anti-CCP does not exclude RA · Uric acid (gout) · HLA-B27 not routine — supportive only in selected suspected axial SpA
Connective tissue disease
ANA and specific antibodies (dsDNA, Anti-Ro/La) only when connective-tissue disease is clinically suspected — ANA is not a general screen for unexplained aches; a positive ANA without compatible features is usually non-diagnostic and should not automatically trigger referral
Myopathy screen
CK when true weakness or myositis suspected — a normal CK does not exclude all inflammatory myopathy · Aldolase, LDH and myositis-specific antibodies usually specialist-directed · urinalysis, renal function and ECG/troponin if severe myositis or rhabdomyolysis suspected
Myeloma (clinical suspicion, not age alone)
Serum protein electrophoresis + serum free light chains if persistent focal bone pain, unexplained anaemia, hypercalcaemia, renal impairment, raised ESR/PV, recurrent infection, weight loss, pathological fracture or paraprotein suspicion. Urine Bence-Jones generally unnecessary where free light chains are available — follow local laboratory and suspected cancer pathways.
Renal / vasculitis
Urinalysis + urine ACR/PCR for suspected renal or vasculitic disease
NOT routinely
A universal panel for new aches. CK, vitamin D, ANA, RF/anti-CCP or HLA-B27 without a clinical indication (e.g. ANA in fibromyalgia without features of CTD) — leads to false positives and over-investigation.
Targeted rather than universal testing avoids false positives and repeated investigation. CK is the key test when there is objective proximal weakness, but a normal CK does not exclude all inflammatory myopathy. Anti-CCP is highly specific for RA and should be checked when there is an inflammatory arthritis pattern — but do not wait for it before referring convincing synovitis. Requesting ANA in all patients with aches is a common error — low-titre positives occur in healthy people and lead to unnecessary anxiety and specialist referrals.
6
Refer

Referral Criteria

Same-day
Suspected GCA — same-day clinical assessment via local GCA pathway; visual or neurological symptoms → emergency same-day ophthalmology/acute assessment; do not delay steroids for blood results. Progressive true proximal weakness, dysphagia or respiratory weakness → same-day acute medical assessment + specialist discussion. Sepsis or suspected septic arthritis. Severe hypercalcaemia or acute kidney injury. Suspected vasculitis with renal, pulmonary or neurological involvement.
Suspected cancer · haematology
Suspected myeloma: persistent bone pain, unexplained anaemia, hypercalcaemia, renal impairment, raised ESR/PV, paraprotein on electrophoresis — age plus aches alone is not enough · NICE NG12: aged 60+ with persistent bone pain (particularly back pain) or unexplained fracture → offer urgent FBC, calcium, ESR/PV, serum protein electrophoresis and serum free light chains (urine Bence-Jones protein if free light chain testing is unavailable); if results suggest myeloma → suspected cancer pathway referral (NICE NG12, updated April 2026)
Urgent rheumatology / early inflammatory arthritis pathway
Objective synovitis, persistent swollen joints, small-joint involvement, suspected inflammatory arthritis, inflammatory back pain with compatible features, suspected CTD with clinical organ involvement, suspected vasculitis, suspected inflammatory myopathy. Do not wait for RF, anti-CCP, ANA or HLA-B27 when clinical findings are convincing. PMR: atypical presentation, normal inflammatory markers, poor steroid response, relapse or prolonged steroid dependence.
Routine rheumatology
Genuine diagnostic uncertainty in widespread pain, psoriatic arthritis, SpA. Typical fibromyalgia (typical history and examination, no red flags, reassuring targeted tests) does not need rheumatology referral — routine referral may reinforce repeated investigation.
Endocrinology
Cushing's syndrome (proximal myopathy + cushingoid features), Addison's disease (generalised aches + postural hypotension)
Early specialist DMARD treatment in inflammatory arthritis reduces joint damage — refer on clinical synovitis rather than waiting for autoantibody results. The NICE NG12 myeloma tests (very urgent, within 48 hours, if hypercalcaemia or leukopenia) require serum protein electrophoresis — not all myeloma is detected on FBC alone, and a normal Hb does not exclude myeloma. PMR with relapse, poor steroid response or prolonged steroid dependence needs specialist review, including consideration of steroid-sparing agents.
7
Treat

Treatment Ladder

PMR (after excluding mimics)
Trial of prednisolone 15 mg OD
BSR/BHPR PMR guideline (2010). A response does not confirm PMR; poor response → reconsider the diagnosis. Taper per local PMR protocol, individualised to symptoms, inflammatory markers, relapse and steroid toxicity. Bone protection and fracture-risk assessment; monitor glucose, blood pressure, cataract, infection and osteoporosis. Ask about GCA symptoms at every review. Issue an NHS Steroid Emergency Card (prednisolone 5 mg daily or more, or equivalent, for 4 weeks or longer), give sick-day advice, and do not stop prednisolone abruptly (adrenal insufficiency risk).
Fibromyalgia
Amitriptyline 10–50 mg nocte
Off-label for chronic primary pain; consider after shared decision-making (NICE NG193, 2021). Start low (10 mg), review at 4–6 weeks; stop if ineffective or poorly tolerated. Duloxetine 60 mg OD — one of the antidepressants NICE NG193 says to consider for chronic primary pain, including fibromyalgia, in adults 18+ (off-label). Antidepressants may help pain, sleep, quality of life and distress even without depression. Avoid combining serotonergic drugs without review. Do not initiate opioids, NSAIDs, paracetamol or gabapentinoids (pregabalin, gabapentin) for chronic primary pain (NICE NG193).
Vitamin D deficiency (confirmed)
Colecalciferol — per local formulary
Do not prescribe high-dose vitamin D for non-specific aches without confirming deficiency and considering alternative causes. Use the local formulary and current product information for loading regimens. Not every 25–50 nmol/L level needs treatment — depends on symptoms, risk factors and context. Consider calcium before high-dose replacement where relevant. Review adherence and clinical response; routine repeat testing is not required in every patient.
Statin myalgiaAssess timing vs statin start/dose change, distribution, severity, weakness vs pain, CK, TFTs, renal/liver function, interacting medicines (vitamin D only if clinically appropriate). Marked weakness, dark urine, AKI or markedly raised CK → urgent assessment (rhabdomyolysis). Dechallenge/rechallenge is useful but not diagnostic in isolation. Confirmed or probable intolerance: lower dose, different statin, intermittent dosing, or ezetimibe/other lipid-lowering per cardiovascular-risk guidance; specialist lipid advice where needed.
Viral myalgiaUsually self-limiting — reassurance and diagnosis-specific, risk-adjusted symptomatic care for the acute illness. Persistent symptoms → reassess. Ask about post-exertional malaise; if ME/CFS suspected, follow NICE NG206 and do not prescribe graded exercise therapy.
RA / inflammatoryNaproxen 500 mg BD short-term bridge. DMARDs (methotrexate 7.5–25 mg weekly) — initiated by rheumatology. Do not delay referral waiting for DMARD initiation in GP.

Next steps: see Polymyalgia rheumatica · Giant cell arteritis · Chronic primary pain · ME/CFS

A prednisolone response does not confirm PMR — many inflammatory and non-inflammatory conditions improve with steroids — but failure to respond should prompt reconsideration of the diagnosis, especially malignancy. NICE NG193 supports considering an antidepressant (e.g. amitriptyline or duloxetine, off-label) for chronic primary pain after shared decision-making, reviewed and stopped if ineffective. Treat vitamin D deficiency only when confirmed, and review whether symptoms actually respond.
8
Lifestyle

Non-Pharmacological Management

Explain & validate Person-centred assessment; explain fibromyalgia/chronic primary pain positively and validate symptoms (NICE NG193).
Exercise (non-PMR/myositis) NICE NG193 (2021) recommends offering a supervised group exercise programme for chronic primary pain, including fibromyalgia. Water-based exercise may suit some (reduced impact). Do not use graded exercise therapy if ME/CFS is suspected (NICE NG206).
Physiotherapy Hydrotherapy, targeted exercise programme, manual therapy for specific joints. Supervised exercise is recommended for fibromyalgia in NICE NG193 (2021) — refer early.
CBT or ACT for pain Pain-focused CBT or acceptance and commitment therapy (ACT) — NICE NG193 says to consider these for chronic primary pain (age 16+). Refer via NHS Talking Therapies.
Sleep optimisation Sleep disturbance amplifies pain perception — address sleep and activity management; consider CBT-I (CBT for insomnia).
Pacing (fibromyalgia/CWP) Energy pacing — avoid boom-bust cycles. Activity diaries. Occupational therapy referral. Return to activity gradually without triggering flares.
Vitamin D — safe sun & diet Follow UK public-health advice on safe sun exposure (avoid sunburn) and dietary sources of vitamin D such as oily fish, eggs and fortified foods.
Alcohol & smoking Alcohol worsens musculoskeletal pain (dehydrates muscle, worsens sleep). Smoking associated with higher fibromyalgia severity and inflammatory arthritis activity.
Stress management Stress is a major pain amplifier. Mindfulness-based approaches may help some people — local programmes or NHS Talking Therapies.
NICE NG193 (Chronic Primary Pain, 2021) advises not initiating opioids, NSAIDs, paracetamol or gabapentinoids for chronic primary pain, instead prioritising person-centred assessment, supervised group exercise, CBT or ACT for pain, and (after shared decision-making) selected antidepressants. Chronic widespread pain involves central sensitisation rather than ongoing tissue damage, so a positive explanation and active self-management are central.
9
Safety

Follow-Up & Safety-Netting

4–6 weeks
Review investigation results. PMR: response, mimics reconsidered, GCA symptoms? Antidepressant: benefit and tolerability — stop if ineffective. Vitamin D (if treated): adherence and clinical response? Statin: symptoms after dechallenge? Persistent post-viral symptoms: reassess.
3 months
Fibromyalgia review — pain scores (NRS), sleep quality, function, psychological wellbeing. Adjust medication. Physiotherapy progress.
PMR monitoring
Per local PMR protocol: symptoms, ESR/CRP, relapse and steroid toxicity. Ask about GCA symptoms at every review. Bone protection and fracture-risk assessment; monitor glucose, blood pressure, cataract, infection and osteoporosis. Warn about GCA symptoms — headache, jaw claudication, visual disturbance → same-day emergency assessment (999 if sudden visual loss)
Statin re-challenge
Rechallenge with a lower dose, different statin or intermittent dosing. If intolerance is confirmed or probable → ezetimibe or other lipid-lowering treatment per cardiovascular-risk guidance; specialist lipid advice where needed.
999 safety-net
Sudden visual loss (GCA complication), acute severe or respiratory weakness, acute confusional state, sepsis, haemodynamic compromise
Same-day GP
New scalp tenderness or jaw claudication in PMR patient (GCA develops in a clinically important minority of PMR), progressive weakness, dysphagia, dark urine, hot swollen joint, new rash + arthralgia
A clinically important minority of PMR patients develop GCA, and the risk persists throughout treatment. All PMR patients must be educated about GCA symptoms and told to seek same-day review if they develop headache, jaw claudication, scalp tenderness or visual disturbance. Long-term steroids cause osteoporosis and fractures — fracture-risk assessment and bone protection are essential. Statin rechallenge at a lower dose or with a different statin is often tolerated and is preferable to abandoning lipid-lowering given cardiovascular benefits.
Educational use only. Based on BSR/BHPR PMR guideline (2010), BSR GCA guideline (2020), NICE NG193 (Chronic Primary Pain, 2021), NICE NG100 (Rheumatoid Arthritis, 2018), NICE NG12 (updated April 2026), NOS Vitamin D and bone health guideline, BSR idiopathic inflammatory myopathy guideline (2022), NICE NG206 (ME/CFS, 2021), local Formulary (musculoskeletal and joint diseases). Always adapt to individual patient context.